Reducing Costs, Improving Outcomes
Renalytix AI is committed to helping payors of all sizes reduce costs while improving the quality of care in patients’ lives. Our KidneyIntelX test is designed to help healthcare providers make actionable clinical management decisions, while reducing costly care and providing better outcomes for patients in need.
Value-Based Approach Informs Better Care
KidneyIntelX is designed to improve identification and clinical management of patients with Type 2 diabetes with fast-progressing kidney disease to reduce the estimated $114 billion annual cost of chronic and end-stage kidney disease to the United States healthcare system.
KidneyIntelX uses machine learning algorithms to assess a combination of predictive blood-based biomarkers and clinical data from a patient’s electronic health record to provide a KidneyIntelX Risk Score. This Risk Score is used to determine which patients with CKD are at low, intermediate, or high risk of rapid kidney function decline within 5 years.
Making an Impact on a Public Health Crisis
Dedicated CPT® Code
The American Medical Association (AMA) has granted a CPT® Proprietary Laboratory Analyses Code for KidneyIntelX. The code, 0105U, has been approved and published by the AMA CPT Editorial Panel, and is effective as of October 1, 2019.
RenalytixAI Labs Overview
Our CLIA-certified diagnostic labs are committed to supporting clients through unparalleled quality and service. We have locations in Salt Lake City and New York City.
New York Lab
Renalytix AI’s New York state-of-the-art reference laboratory is situated in the New York Genome Center in Lower Manhattan.
101 6th Avenue, 3rd FL
New York, NY 10013
Salt Lake City Lab
Renalytix AI’s Utah state-of-the-art reference laboratory is located on the University of Utah Research Park campus.
421 Wakara Way, Suite 309,
Salt Lake City, UT 84108
If you are a payer or insurance provider, please contact our Market Access team to learn more about our KidneyIntelX test:
VP, Market Access